Drug or intervention
Empagliflozin Clinical Trials
Studies that test Empagliflozin, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 144Healthy
A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
The main objective of this trial is to establish the bioequivalence of two different formulations of vicadrostat / empagliflozin in healthy male and female trial participants following oral administration.
- Trial name
- NCT07845630
- Testing
- Vicadrostat, Empagliflozin, Vicadrostat + empagliflozin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disease, often compounded by obesity, that leads to serious long-term health complications.
- Trial name
- NCT07728318
- Testing
- Tirzepatide + Standard Therapy (Intervention Group), Standard Oral Antidiabetic Drugs (OADs)
- Volunteers
- 52 people
- Sponsor
- Akhtar Saeed Medical and Dental College
Heart Failure
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more.
- Trial name
- NCT06424288
- Testing
- vicadrostat, empagliflozin
- Where
- 671 sites in United States, Argentina and 28 more
- Volunteers
- 6,712 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding…
- Trial name
- EMPA-RRED (NCT06249932)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Heart Failure
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%.
- Trial name
- NCT06935370
- Testing
- vicadrostat, empagliflozin
- Where
- 594 sites in United States, Argentina and 27 more
- Volunteers
- 4,200 people
- Sponsor
- Boehringer Ingelheim
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Study Background \& Purpose: The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI).
- Conditions
- No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT07898709
- Testing
- Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment
- Where
- 4 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Kidney Stone, Nephrolithiasis
Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for…
- Conditions
- Kidney Stone, Nephrolithiasis, Dietary Exposure
- Trial name
- EMPASTONE (NCT06653738)
- Testing
- Empagliflozin 10 MG, Personalized dietary counseling, Generic dietary counseling
- Where
- 21 sites in France, Germany and 2 more
- Volunteers
- 400 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Obesity, Vascular Health
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
- Trial name
- EMPA (NCT06745063)
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VA Office of Research and Development
End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
Empagliflozin, a new class of diabetes medication, has demonstrated a reduction in renal function decline among patients with chronic kidney disease, regardless of their diabetes status.
- Conditions
- End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication, Sodium-glucose Cotransporter-2 Inhibitor, Residual Kidney Function
- Trial name
- EMPIRIC-PD (NCT06483074)
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 48 people
- Sponsor
- Chinese University of Hong Kong
Completed, with results posted
All 129End-stage Kidney Disease, Kidney Disease, Chronic
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients.
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic
- Trial name
- NCT05614115
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Utah
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - Combo INI+EMPA Trial
The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2…
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05081219
- Testing
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Autosomal Dominant Polycystic Kidney Disease
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
- Trial name
- SIDIA (NCT06435858)
- Testing
- Empagliflozin
- Where
- 2 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- Cantonal Hospital Graubuenden
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Heart Failure
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
- Trial name
- NCT05236673
- Testing
- JARDIANCE®
- Where
- 21 sites in South Korea
- Volunteers
- 676 people
- Sponsor
- Boehringer Ingelheim